Skip to content

L-Carnitine Administration in Early Sepsis

L-Carnitine Administration in Early Sepsis

Status
Terminated
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01193777
Enrollment
31
Registered
2010-09-02
Start date
2010-09-30
Completion date
2012-02-29
Last updated
2022-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Septic Shock

Keywords

Carnitine, Shock, Sepsis

Brief summary

Sepsis is a severe and overwhelming response to an infection in the body. Over 750,000 patients in the United States develop sepsis every year. As sepsis becomes progressively more severe, a patient's blood pressure drops to dangerous levels and the body cannot pump oxygen to the rest of the body, which is necessary for normal cell function. This is called septic shock. When someone develops septic shock, it is very common for the smallest blood vessels in the body called the microcirculation to clog, like a highway during rush hour. Even with the best medical care, more than one in three patients with septic shock will die. The major goal of this study is to test if intravenous replacement of a naturally occurring nutrient that is lost by the body during sepsis called L-carnitine can reduce how sick a patient with sepsis becomes. In our study, some patients will receive L-carnitine and others will receive saline. We will measure markers determining severity of illness in both groups and compare them to see if L-carnitine helps patients get better faster. Based on research already conducted, we believe L-carnitine will improve blood flow in the microcirculation, delivering more oxygen to cells, and help the body get better. To test if this is true, we will directly look at the microcirculation under the tongue with a special magnifying camera that looks at red blood cells, and compare both groups.

Interventions

DRUGL-Carnitine

4 gram bolus followed by 8 gram in 1 L NS infused over 12 hours.

DRUGNormal Saline

Bolus followed by 1 L NS infusion over 12 hours.

Sponsors

American Heart Association
CollaboratorOTHER
Wake Forest University Health Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Suspected or confirmed infection * Any two of four criteria of systemic inflammatory response * Requirement for vasopressors to treat shock * Enrollment within 12 hours of vasopressor initiation * SOFA score of greater than or equal to 5 at the time of enrollment

Exclusion criteria

* Age \<18 years * Pregnancy or breastfeeding * Any primary diagnosis other than sepsis * Established Do Not Resuscitate status or advanced directives restricting aggressive care or treating physician deems aggressive care unsuitable * Any history of seizures or a known seizure disorder * Any known inborn error of metabolism * Anticipated requirement for surgery that would interfere with the 12 hour infusion time * Active participation in another interventional study * Inability to obtain informed consent * Cardiopulmonary resuscitation (chest compression or defibrillation) prior to enrollment * Known systemic allergy to carnitine

Design outcomes

Primary

MeasureTime frameDescription
Reduction in organ failure24 hoursSOFA score will be measured at 0 and 24 hours

Secondary

MeasureTime frameDescription
Microcirculation12 hoursTest if carnitine improves blood flow in the sublingual microvasculature during septic shock by performing sidestream dark-field (SDF) video-microscopy of the sublingual microcirculation, prior to and after 12 hours of carnitine infusion.
ICU and hospital length of stayDuration of stay
All-cause mortality28 day
Change in inflammatory markers12 hoursAssess change in various inflammatory markers over predefined time points.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026